This site is intended for healthcare professionals residing in Canada.

Visit Pfizer AcademySearch

Menu

Close

Sign InLog Out
  • EN
ProductsTherapy AreasExplore ContentExplore
ContentGo to Explore ContentEventsMaterialsVideosPatient SupportContact
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Français

Menu

Close

About Prevnar 20About Prevnar 2020 SerotypesMechanism of actionImmunogenicity profileSafety profileDosing and administrationDosing and administrationDosingAdministrationInvasive pneumococcal diseaseInvasive pneumococcal diseaseDisease burden in infants and childrenSerotype distributionGuidelinesResourcesResourcesMaterialsVideos
Safety InformationProduct MonographPrevnar 20 Adult
Mechanism of ActionA pneumococcal conjugate vaccine with enhanced antibody response1*POLYSACCHARIDE VACCINE1

The immune response to a pure polysaccharide vaccine involves the production of antibodies by B-cells, and is typically T-cell independent.1

CONJUGATE POLYSACCHARIDE

Protein conjugation changes the immune response from T-cell independent to T-cell dependent, enhancing antibody response via memory B-cells and inducing immune memory.1

Adapted from the Prevnar 20 Product Monograph.

Conjugated polysaccharide vaccines, such as Prevnar 20, stimulate the immune system to generate:1*

  • High-affinity antibodies
  • Long-lived B-cells
  • Immune memory

In pediatric patients, the serotype-specific IgG levels that correlate with protection against pneumococcal disease have not been clearly defined.

* Comparative clinical significance is unknown.

Reference:Prevnar 20™ Product Monograph. Pfizer Canada ULC.About NEXT

Immunogenicity data

 Visit page Loading EXPLORE MORE

Invasive pneumococcal disease

 Visit page Loading
PP-PNR-CAN-0106-EN

To report an adverse event, please call 1-866-723-7111

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign in or RegisterSign inRegisterAccountSign Out

© Pfizer Canada ULC 2024. All rights reserved. The information is intended only for healthcare professionals resident in Canada. ®Pfizer Inc., used under license.

PP-UNP-CAN-0145-EN
You are now leaving Pfizerpro.ca website
Links to other sites are provided as a convenience to the viewer, and should not be taken as an endorsement of the sites or an association with their owners. Pfizer Canada accepts no responsibility for the content of linked sites.
You are now leaving the PfizerPro Portal.
You are about to view resources made available by Pfizer Academy. 
These resources include learning programs and upcoming events. By selecting Go to link below, you acknowledge and certify that you are a Canadian Healthcare Professional.
PP-UNP-CAN-0013 EN